Eli Lilly's Mounjaro ↗ booked $8.66 billion in Q1 2026 sales, ahead of Merck's Keytruda at $7.9 billion in the same quarter, crystallizing in the analyst cycle this week ↗ what Bloomberg first framed on May 6. The shift makes tirzepatide ↗ the top-selling pharmaceutical in the world and ends Keytruda's two-year run at number one, a position the anti-PD-1 antibody had held since it displaced AbbVie's Humira in early 2023. It is the first time a peptide therapeutic has taken the world's number-one drug spot since the historical era of insulin biosimilars, and the first time in the modern industry that the top-selling drug is neither an immuno-oncology agent nor a chronic-disease biologic but a metabolic peptide sold for weight loss and diabetes.
The numbers in context. Mounjaro on its own is a single brand for tirzepatide in the type-2 diabetes indication. The full tirzepatide platform that combines Mounjaro with Zepbound ↗ (the obesity brand) generated $36.5 billion in 2025 against Keytruda's $31.6 billion. The Q1 2026 Mounjaro-vs-Keytruda comparison is the cleaner single-brand snapshot, but the platform-vs-platform comparison is the structural one. Keytruda still anchors a deeper indications portfolio (more than thirty approved on-label uses across hematologic and solid tumors, with the most recent expansions in MSI-high colorectal cancer and adjuvant non-small-cell lung cancer) and has additional commercial life through its biosimilar-protection window into 2028. Tirzepatide is a younger franchise on a steeper growth curve, with the obesity indication still scaling and the additional indications (heart failure with preserved ejection fraction in SUMMIT, sleep apnea, MASH, alcohol use disorder explored in earlier sections of this news coverage) widening the addressable population each quarter.
What changes for the field. The world's number-one drug being a peptide is a structural shift more than a symbolic one. Three things follow.
First, manufacturing capacity stops being an afterthought. Lilly's $4.5 billion Lebanon Indiana recommitment ↗ at the May 6 ribbon-cutting brought total Indiana capital commitments past $21 billion since 2020. The LEAP District alone is $18 billion since 2022, the largest capital project in Indiana history. The investment is the supply-chain answer to the same demand that drove the 2022 GLP-1 shortage, and the size of the investment matches what a number-one-globally drug actually requires. PolyPeptide expanded its credit facility to EUR 200 million in May to fund a Malmö capacity buildout. CordenPharma announced a $500 million Boulder SPPS expansion last quarter. Catalent's TIDES USA 2026 presence centers on oral macromolecule delivery for peptides up to 100,000 daltons. The peptide CDMO build-out, which has been quietly underway through the early GLP-1 demand cycle, is now positioned to support the largest drug-class commercial print on the market.
Second, indication breadth becomes the strategic question. Keytruda's success was structurally driven by indication expansion, and the pattern is the precedent every analyst will now apply to tirzepatide. Lilly has heart failure (SURMOUNT-HF), MASH (SYNERGY), alcohol use disorder, and sleep apnea (SURMOUNT-OSA) all on the active-program docket. The tirzepatide indication-expansion plan is plausibly the most ambitious of any drug program in the industry. Each successful Phase 3 readout in a new indication adds incremental addressable population and incremental revenue, in the same way the Keytruda label-expansion machine drove the brand's commercial trajectory from 2018 through 2024.
Third, the pricing-and-access conversation moves to a new venue. The world's number-one drug is on the receiving end of a different kind of policy scrutiny than the number-three or number-five drug. CMS Medicare negotiation, the CMS GLP-1 Bridge extension to 2027 covered earlier in this news cycle, the Foundayo and Wegovy ↗ pill pricing-and-coverage dynamics, the state-level access disparities covered last month: all of these conversations operate on a different time horizon and at a different political profile when the underlying drug is the largest commercial product in pharmacy. Tirzepatide arriving at number-one accelerates the timeline on most of those discussions.
The platform read. The GLP-1R ↗ and GIPR ↗ targets that tirzepatide engages are the most-traveled section of the platform's corpus, hosting the agonist scaffolds that anchor the modern obesity-peptide design space. Mounjaro overtaking Keytruda is not the platform's story but is the commercial weather around the corner of the corpus that gets the most experimental work and the most clinical interest. The pep-00017 ↗ card and the adjacent retatrutide ↗, survodutide ↗, MariTide ↗, and the broader incretin-agonist set sit on a target whose lead drug is now the largest pharmaceutical brand in the world. The follow-on programs covered in this news section over recent weeks (the Lilly quintuple agonist preview, the CagriSema body-composition data, the Ascletis once-monthly programs, the MBX 4291 monthly-dosing platform, Viking VK2735, AstraZeneca eleglipron) are competing not for a corner of an emerging market but for share of the world's largest drug class.
What this is not. A permanent ranking. Quarterly best-selling drug positions move with launch cycles, IRA Part D negotiation outcomes, biosimilar timing, and patent cliffs. Keytruda's loss-of-exclusivity in 2028 is a separate question that affects the structural comparison more than this single-quarter comparison does. What this is is a clean signal that the peptide therapeutic class has moved from a notable subset of pharmacology into the commercial center of the industry, and that the engineering, manufacturing, regulatory, and pricing infrastructure that supports peptide drugs now needs to operate at top-of-market scale.